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We have tested the sequence UUC CAG UCA GAC CU, at position 9016–9029 within the HIV-1SF2 nef open reading frame,
for accessibility to antisense and hammerhead ribozyme attack. The accessibility was first studied using a phosphorothioate-
modified 14-nt DNA oligo (complementary to the nef9016–9029 site). A dose-dependent repression of HIV-1SF2 growth was
observed in human peripheral blood mononuclear cells after exogenous administration of the oligo to the cell culture medium.
A hammerhead ribozyme with a 6/7-nt antisense specificity for the nef9016–9029 site (hhRz.nef9016–9029) was constructed and
transfected into the human T-cell line HUT78. Again, a dose-dependent repression of virus growth was observed when
different individual clones expressing hhRz.nef9016–9029 were infected with HIV-1SF2 . A complete abrogation of virus production
was observed after infection with a low (0.5 TCID50) HIV-1 titer. Increasing doses (2.5 and 12.5 TCID50) of HIV-1 virus yielded
a low production (103-fold reduced) of virus particles in most cases; but a complete, or close to complete, abrogation was
observed even in individual cultures infected with the highest dose. Presence of proviral pol and gag sequences in
hhRz.nef9016–9029-expressing HUT78 clones was assayed, using PCR. Interestingly, since no pol and gag PCR products could
be detected, the results strongly indicated that the hammerhead ribozyme was already acting on the infecting HIV RNA
before its reverse transcription and integration as proviral DNA. In summary, the results obtained in this study support the
nef9016–9029 site as a strong new candidate for ribozymal gene therapy against HIV-1 infection. q 1996 Academic Press, Inc.
INTRODUCTION Ventura et al., 1994). One major reason for targeting the
LTR has been that it is involved in initiation of and is
HIV infection can be defined as a ‘‘genetic disease,’’ included in all mRNAs produced during the infection.
following the integration of proviral DNA into the host’s Other targets have been sequences which code for regu-
cellular genome, thus identifying HIV infection as a target latory proteins such as factors increasing virus produc-
for gene therapy. tion, e.g., tat and rev (Lo et al., 1992; Crisell et al., 1993;
Ribozymes have been considered therapeutic agents Zhou et al., 1994). Yet another strategy has been to target
that could be used to combat infectious diseases, partic- sequences which code for structural proteins such as
ularly viruses, where antibiotics, immunization, and drugs pol, gag, and env (Sarver et al., 1990; Sioud and Drlica,
are unsuccessful (Sullivan, 1994; Rossi, 1995). ‘‘Tailor- 1992; Chen et al., 1992; Homann et al., 1993; Joseph
made’’ ribozymes have been used successfully in several and Burke, 1993). Furthermore, several refinements to
studies to target HIV-1 mRNA expression in cell-free sys- increase the efficacy of ribozyme targeting have been
tems as well as in vitro studies in mammalian cell lines made. One example is to increase the number of ribo-
(for a review see Rossi and Sarver, 1992; see also below). zymes to target a specific region, e.g., Chen et al. (1992),
A clinical protocol to evaluate the safety and feasibility who made a construct with nine different ribozymes di-
of using an anti-HIV-1 hairpin ribozyme in AIDS patients rected against the env region. Other refinements have
has recently been approved by the NIH Recombinant
been to use specific guide sequences linked to the ribo-
DNA Advisory Committee (Yu et al., 1994).
zyme, such as the specific tRNA sequence that primes
Different approaches for ribozymal targeting of the
the reverse transcriptase (Larson et al., 1993) or to in-
HIV-1 genome have been used. A well-studied region
clude a sequence (the retroviral packaging signal) which
is the LTR promoter region (Weerasinghe et al., 1991;
colocalizes the ribozyme with the targeted RNA (Sul-Goodchild and Kohli, 1991; Dropuli*c et al., 1992; Jeang
lenger and Cech, 1993).and Berkhout, 1992; Heidenreich and Eckstein, 1992;
In summary, most RNAs produced during the HIV-1
infection cycle have been targeted, such as LTR, gag,
pol, and env. One striking exception is the nef region,1 To whom correspondence and reprint requests should be ad-
dressed. located at the 3*-end of the genome and present in all
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FIG. 1. Structure of the HIV-1 genome. The open reading frames in the HIV-1 genome are illustrated and the HIV-1SF2 nef9016–9029 target site is
also indicated.
transcripts and splice forms generated during the HIV quence and 2 had one mismatch each. Four reported
HIV-1 subtype O sequences showed one, two, two, andlife cycle. The Nef, for ‘‘negative factor,’’ protein is a 25-
to 27-kDa cytoplasmic protein translated early during the three mismatches, respectively, while 1 subtype O se-
quence showed only rudimentary homology to theinfection cycle (for a review see Subbramanian and Co-
hen, 1994). The function of Nef is uncertain. Nef has nef9016 – 9029 sequence.
The phosphorothioate oligonucleotide, complemen-previously been suggested to be a repressor or silencer
(Ahmad and Venkatesan, 1988; Niederman et al., 1989), tary to the target sequence, was purchased from Appli-
gene.but has lately been suggested to be involved in activation
of HIV gene expression by de-inhibition of NFkB (Kerr, A hammerhead ribozyme (hhRz.nef9016 – 9029) (Fig. 1) tar-
geting the same nef9016 – 9029 position was cloned into a1995). Furthermore, Nef induces CD4 endocytosis (Aiken
et al., 1994), and studies in rhesus monkeys have shown ‘‘basal’’ ribozyme vector as described in detail previously
(Larsson et al., 1994). In short, the pNef1a plasmid wasthat the SIV nef gene is necessary for progress to clinical
disease (Kestler et al., 1991). In two recent published generated the following way: complementary oligos con-
taining the recognition sequence were synthesized forpapers Nef has been shown to increase the efficiency
of reverse transcriptase in infected cells (Schwartz et the hhRz.nef9016 – 9029 ribozyme (on-site oligosynthesis),
annealed, and exchanged for the MluI/BglII fragment ofal., 1995) and to stimulate HIV-1 proviral DNA synthesis
(Aiken and Trono, 1995). the basal ribozyme vector.
In the present study we present a functional ribozyme
target site in the nef open reading frame. DNA sequencing
The ribozyme clones were sequenced by use of the
MATERIALS AND METHODS
T3 sequencing primer 5*-dATTAACCCTCACTAAAG-3*
(Pharmacia LKB Biotechnology). The DNA sequencingAntisense and ribozyme design and cloning
reaction was performed as described by Applied Biosys-procedures
tems using the Taq DyeDeoxy termination cycle se-
A 14-nucleotide-long sequence (UUC CAG UCA GAC quencing kit and analyzed in an automatic 373A DNA
CU) within the nef open reading frame at position 9016 – sequencer.
9029 in the HIV-1SF2 genome (nef9016 – 9029) was selected
as a target for an antisense DNA oligo (Fig. 1). The con- Cells, transfections, and HIV-1 and herpes simplex
servation of the target sequence between different HIV- virus type I infections
1 subtypes, as listed in the Los Alamos National Labora-
tory database (January 1996), is shown in Table 1. Briefly, Human peripheral blood mononuclear cells (PBMC)
were isolated and cultivated as described previously (So¨n-for the HIV-1 subtype A 1 sequence is reported and con-
tains four mismatches. For the HIV-1 subtype B, to which nerborg et al., 1990). In a typical oligonucleotide experi-
ment 1 1 105 cells/well (96-well plate) were cultivated inSF2 belongs, 28 different sequences were reported in
the database. Seventeen of these showed complete ho- 200 ml medium. Three hours prior to the addition of virus
the cells were incubated with a nef-specific or a controlmology with the target site and 11 showed one mismatch.
Three sequences were reported for subtype D, of which oligonucleotide (0.2, 1.0, or 5.0 mM) or without any oligo-
nucleotide. After 1 hr of virus (1 TCID50 HIV-1SF2) adsorp-1 was completely homologous to the nef9016 – 9029 se-
AID VY 7880 / 6a15$$$282 04-04-96 11:40:18 vira AP: Virology
163RIBOZYME STRATEGIES FOR HIV GENE THERAPY
TABLE 1
Sequence Comparisons between nef9016–9029 and Reported HIV Substrains in the Los Alamos National Laboratory Database (January 1996)
nef9016–1929 T T C C A G T C A G A C C T
Consensus A – C – – – – – T – – G – – A
HIVU455 – C – – – – – T – – G – – A
Consensus B – – – – – – – – – – – – – –
HIVLA1 – – – – – – – – – C – – – –
HIVNL43 – – – – – – – – – C – – – –
HIVGLNEF3 – – – – – – – G – – – – – –
HIVGLNEF5 – – – – – – – – – C – – – –
HIVGLNEF6 – – – – – – – – – C – – – –
HIVBRVA – – – – – – – – – A – – – –
HIVMN – – – – – – – – – A – – – –
HIVSC – – – – – – – – – – – – – –
HIVBAL1 – – – – – – – – – – – – – –
HIVJRCSF – – – – – – – – – – – – – –
HIVJRFL – – – – – – – – – – – – – –
HIVNH53 – – – – – – – – – – – – – –
HIVOY1 – – – – – – – – – – – – – –
HIVSF2 – – – – – – – – – – – – – –
HIVSF162 – – – – – – – – – – – – – –
HIVCAM1 – – – – – – – – – – – – – –
HIVHEI20BL – – – – – – – – – – – – – –
HIVHEI28BL – – – – – – – – – R – – – –
HIVHEI39BL – – – – – – – – – – – – – –
HIVHEI3BL – – – – – – – – – – – – – –
HIVHEI4BL – – – – – – – – – – – – – –
HIVSF33 – – – – – – – – – A – – – –
HIVSWB84 – – – – – – – – – – – – – –
HIVHAN – – – – – – – – – – – – – A
HIVD31 – – – – – – – – – A – – – –
HIVRF – – – – – – – – – – – – – –
HIVYU2 – – – – – – – – – – – – – –
HIVBCSG3C – – – – – – – – – – – – – –
Consensus D – – – – – – – – – – – – – –
HIVELI – – – – – – – – – – – – – C
HIVNDK – – – – – – – T – – – – – –
HIVZ6 – – – – – – – – – – – – – –
Consensus O – – – – – – – ? – – – – – ?
HIVMAL – – – – – – – – C – T – – –
HIVZ321 – – – – – – – – – – – – – A
HIVANT70 – – – – – – – A G C – – – –
SIVCPZGAB – – – – – – – A – – – – – A
HIVMVP5180 C C T T T – A – C T C A G C
tion the cells were washed repeatedly with phosphate- tected in nontransfected cells. In contrast, HUT78 cell
colonies were growing in the flasks with the transfectedbuffered saline and new oligonucleotide-containing me-
dium was added. For the p24-antigen test 100 ml super- cells. Twenty-six clones were picked and expanded to
107 cells for further analysis. Close to 100% of the clonesnatant/medium was collected at time points indicated in
the experiments. The supernatant was replaced with were shown by Southern blot analysis to carry the ribo-
zyme DNA (data not shown).fresh oligonucleotide-containing medium.
Suspension cultures of HUT78 cells were maintained Three ribozyme-expressing HUT78 clones were se-
lected for further experiments. Proliferation was deter-in RPMI 1640 supplemented with 10% (v/v) fetal calf se-
rum and antibiotics (penicillin/streptomycin). Cells (2 1 mined by [3H]thymidine incorporation into the genomic
DNA. The cells, 10,000, 20,000, and 50,000 in triplicate,107) were transfected with 20 mg of the ribozyme con-
struction (linearized using ScaI) together with 0.5 mg of were cultivated 1 hr or overnight (18 hr) in the presence
of [3H]thymidine. At the end of cultivation the cells werea plasmid containing the hygromycin-resistance gene.
The transfection was achieved by electroporation at 960 transferred to a nylon filter and disrupted so the DNA
sticked to the filter. The respective DNAs were trans-mF/240 V (Gene-Pulser, Bio-Rad). Selection for hygro-
mycin resistance was done at 200 mM concentration. ferred to a scintillation tube and scintillation counting
was performed.Two weeks posttransfection no cell growth could be de-
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For each HIV-1 infection, 2 1 106 normal HUT78 or and after 30 min of incubation at room temperature the
reaction was stopped and spectrophotometric measure-ribozyme-expressing cells were used. After the cells
were pelleted the supernatant was discarded and the ment at 492 nm was performed.
cells were resuspended in RPMI culture medium con-
taining polybrene 2 mg/ml. Three different titers, 0.5, 2.5, RESULTS
and 12.5 TCID50 , of the virus (HIV-1SF2) were used. The
A phosphorothioate-modified DNA oligonucleotidevirus adsorption was for 30 min at 377, followed by three
targeting the nef9016 – 9029 sequence inhibits HIV-1washes with RPMI culture medium. The cells were split
infection in huPBMCinto duplicates with 7.51 105 cells/well in 1.5 ml medium
in 24-multidish-well plates and incubated at 377 and 5% The accessibility of the selected nef9016 – 9029 site was
CO2 humidity. Supernatants were collected and fresh me- first tested with an antisense oligonucleotide approach.
dium was added on Days 4, 7, 11, and 14 postinfection. Human peripheral blood mononuclear cells (huPBMC)
HIV-1 p24 antigen, as an indicator of HIV-1 replication, were infected with HIV-1, and infected cells were treated
was assayed on growth medium supernatants. with three different concentrations of the targeted and
The herpes simplex virus type 1 (HSV-1, strain F) infec- control oligo (phosphorothioate modified), 0.2, 1.0, and
tion was performed similarly to the HIV-1 infection. In 5.0 mM. Cell medium supernatants were collected at
short, 2 1 106 HUT78 cells were infected with 1 plaque- Days 3 and 9 and tested in the p24 assay.
forming unit (PFU)/cell. The virus was allowed to adsorb As expected, HIV-1-infected huPBMC cells exhibited
for 30 min, followed by five washes with RPMI culture a progressive p24 production (Fig. 2; non-treated). Treat-
medium. Both supernatants and cells were collected at 4, ment with 0.2 mM oligo concentration showed no or little
24, and 48 hr, freeze/thawed, and analyzed by a plaque- inhibition of the HIV-1 infection compared to nontreated
forming assay. The techniques for preparation of virus cells. Treatment with higher oligo concentrations (1.0 and
stock suspensions and for the plaque assay of virus in 5.0 mM) showed increased inhibition of the HIV-1 infec-
GMK cells have been described in detail elsewhere (Vah- tion compared to nontreated cells. At the highest concen-
lne et al., 1981). tration (5.0 mM) the Nef1a oligo almost completely inhib-
ited virus production at Day 9.
DNA and RNA isolation, DNA blot analysis, RT–PCR, We also used a phosphorothioate-modified control
and PCR oligo with no specificity for the HIV genome. This oligo
showed a partial inhibition at the two highest tested con-Genomic DNA and cytoplasmic RNA were isolated
centrations (1.0 and 5.0 mM; Fig. 2), which probably wasfrom HUT78 cells according to standard procedures, and
due to a general inhibitory effect of the phosphorothioateintegration of the transfected DNA construct was ana-
modification not yet fully understood (Wagner, 1994;lyzed by Southern blot analysis as previously described
Gura, 1995).(Larsson et al., 1994).
Thus, we concluded that the selected nef site wasThe reverse transcription–polymerase chain reaction
accessible to an antisense targeting effect.(RT–PCR) was performed as described in the protocol
from the supplier (GeneAmp RNA PCR kit, Perkin–Elmer
Transfection of HUT78 clonesCetus).
Polymerase chain reaction was performed on genomic Southern-positive clones of HUT78 cells transfected
DNA isolated 14 days postinfection from HUT78 cells with the pNef1a were tested with RT–PCR, and three
and ribozyme-expressing clones 1, 2, and 3. Genomic ribozyme-expressing clones (Fig. 3; clones 1, 2, and 3)
DNA was isolated and dissolved in 100 ml H2O. PCR were further tested for proliferation compared to normal
detecting HLA (DNA control), gag, and pol was performed uncloned HUT78 cells. No significant differences in [3H]-
as before (So¨nnerborg et al., 1990). thymidine incorporation or growth characteristics be-
tween the normal HUT78 cells and the ribozyme-express-
p24 antigen assay (HIVAG-1) ing clones were observed (data not shown). Thus, the
ribozyme expression, per se, did not affect the cellThe protocol supplied by the purchaser (Abbott Labo-
growth.ratories) was followed in detail. Briefly, the supernatant
was added to a p24 antibody (human)-coated bead, HIV-1 infection
treated with Triton X-100 to release p24 antigen, and
incubated for 18 hr at room temperature. After wash a The nef ribozyme-expressing clones 1, 2, and 3 (Fig.
3) and normal HUT78 cells were infected with HIV-1SF2second p24 antibody (rabbit) was incubated for 4 hr at
407. A new wash was followed by incubation with an in two independent experiments which generated similar
results. In each experiment duplicates were infected withanti-rabbit IgG peroxidase-conjugated antibody (goat)
and incubated 2 hr at 407. After another wash OPD (o- three different titers: low, moderate, and high (0.5, 2.5,
and 12.5 TCID50 , respectively). Supernatants were col-phenylenediaminer2HCl) substrate solution was added,
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FIG. 2. An antisense oligonucleotide (phosphorothioate modified) targeting the nef9016–9029 site greatly reduced HIV-1SF2 infection in human
peripheral blood mononuclear cells. Human PBMCs were infected with HIV-1SF2 (1 TCID50) and treated with a nef-specific or a control antisense
oligonucleotide (0.2, 1.0, or 5.0 mM); supernatants were collected at Days 3 and 9 and tested in the HIVAG-1.
lected at Days 4, 7, 11, and 14. Presence of HIV-1 was Detection of proviral DNA in the HIV-1SF2-infected
HUT78 cellstested for by HIVAG-1. Presence of viable HIV-1 particles
was also tested for by using the supernatants for reinfec-
Presence of two HIV genes, pol and gag, were testedtion studies (see below).
for by PCR on genomic DNA isolated 14 days postinfec-A progressive production of p24 antigen was observed
tion. The PCR test confirmed the results obtained with thein HUT78 cultures (Figs. 4A and 4E). In contrast, the
p24 assay. All DNA which originated from p24-positiveribozyme-expressing clones 1, 2, and 3 showed a mark-
samples (values above experimental cutoff levels; Fig.edly reduced p24 production (Figs. 4B–4D and 4F–4H).
4) showed specific PCR products (Figs. 5A, 5B, andThe lowest initial viral load (0.5 TCID50) failed to produce
data not shown). Interestingly, DNA samples froma detectable p24 production in all three tested ribozyme-
hhRz.nef9016 – 9029-expressing clones where p24 levelsexpressing clones. The highest initial viral load (12.5
were below the experimental cutoff (Fig. 4) yielded noTCID50), however, showed an approximately 10
3-fold re-
detectable HIV PCR products (Figs. 5A, 5B, and data notduction in p24 production in all three clones, except for
shown). As expected no pol or gag could be detected inclone 1 which gave no p24 production at all in experiment
2 (Fig. 4F). uninfected cells (Fig. 5). All tested samples were shown
FIG. 3. Expression of hhRz.nef9016–9029 in stable HUT78 transfectants. The hhRz.nef9016–9029 expression (67 nt) is shown in some of the hygromycin-
selected (Southern-positive) HUT78 clones, detected by RT–PCR (Larsson et al., 1994). As a positive RT–PCR control, (/) RNA isolated from NIH3T3
cells expressing a ribozyme with different specificity, Rz-b (69 nt), was used (Larsson et al., 1994). Clones 1, 2, and 3 were selected for infection
with HIV-1.
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FIG. 4. Stable hhRz.nef9016–9029 ribozyme expression in HUT78 cells blocks HIV-1SF2 infection. Two independent infection experiments were
performed on normal HUT78 cells (A and E) and hhRz.nef9016–9029-expressing cells, clone 1 (B and F), clone 2 (C and G), and clone 3 (D and H).
Three different HIV-1SF2 titers, 0.5, 2.5, and 12.5 TCID50 , were used to infect cultures in duplicate. The p24 values were determined from serial
dilutions of supernatants taken at Days 4, 7, 11, and 14 and plotted on a log scale, adjacent bars representing duplicates. The experimental cutoff
value of the assay was 0.09 OD units.
to contain DNA by a PCR reaction amplifying the HLA were added to cultures of normal HUT78 cells, p24 was
assayed for after 7 days in culture, as a measure ofgene (data not shown).
productive infection, and TCID50 values were calculated
for the original supernatants (Fig. 6).Are infectious virus particles produced from the HIV-
Both supernatants from HIV-infected normal HUT781-infected hhRz.nef9016 – 9029-expressing HUT78 clones?
cultures (Fig. 4E) gave a TCID50 value of 6000/ml,
The Day 14 supernatants from the high-dose cultures whereas none of the supernatants from clones 1 and 3
in the second experiment (Figs. 4E–4H) were used in a (Figs. 4F/4H) yielded detectable infectious virus (10
TCID50) when passaged on HUT78 cells. The superna-reinfection assay. Serial dilutions from each supernatant
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FIG. 5. Detection of (A) pol and (B) gag DNA in normal HUT78 cells and in ribozyme-expressing clones 1, 2, and 3 (experiment 1, Day 14, duplicate
1; Figs. 4A–4D). Genomic DNA was isolated and both gag and pol PCR were performed, A and B, respectively. The PCR reaction was performed
in two steps (nested PCR). In the first PCR round a 266-bp pol and a 536-bp gag DNA fragment were generated. In the second PCR round a 174-
bp pol and a 279-bp gag DNA fragment were generated. PCR controls were from HIV-positive DNA (/) and HIV-negative DNA (0).
tants from clone 2 (Fig. 4G) gave a TCID50 value just DISCUSSION
above the experimental cutoff level (10 TCID50).
The results presented strongly support the nef9016 – 9029
site as a new candidate for ribozymal gene therapy
Specificity of the hhRz.nef9016 – 9029 effect against HIV-1. The obtained repression of infection in
ribozyme-expressing HUT78 clones was dose-depen-
We also tested whether the inhibitory effects of the dent and also HIV-1 specific, in the sense that no effect
nef ribozyme were specific to HIV-1 by infecting clones was observed in parallel infections using HSV-1. These
1, 2, and 3 with herpes simplex virus type 1 (HSV-1). The latter experiments also implied that the reduced produc-
ribozyme-expressing clones 1, 2, and 3 were as permis- tion of HIV in the ribozyme-transfected clones was not
sive for HSV-1 infection, i.e., produced as much progeny of an unspecific nature such as is caused by a dif-
virus, as the original HUT78 cells. In one particular exper- ference in metabolic state between the ribozyme-
iment, HUT78 cells and the ribozyme-expressing clones containing and original nontransfected parental HUT78
1, 2, and 3 were infected with HSV-1 (1 PFU/cell), har- cells. Interestingly, there were examples of ‘‘complete’’
vested 48 hr postinfection, and tested for HSV-1 by a resistance to the HIV-1 infection for all the TCID50 doses
plaque-forming assay. The normal HUT78 generated 7.4 tested (0.5, 2.5, 12.5). This complete resistance (indi-1 105 PFU/ml and the clones between 5.9 and 7.4 1 105 cated by no detectable p24 antigen and viable virus)
PFU/ml. was in all cases followed by a lack of integrated proviral
DNA (below the detection level using a sensitive PCR
against pol and gag). We interpret this as evidence that
the hhRz.nef9016 – 9029 ribozyme exhibits an effect immedi-
ately after the infecting HIV RNA has entered the host
cell, prior to the reversed transcription and integration
to proviral DNA. Though a more valid experiment to
examine the ribozyme effect on incoming HIV RNA may
be to analyze the cellular DNA prior to completion of
one infection cycle, i.e., before 24 hr postinfection. The
results do not exclude an effect also on postintegra-
tional events, i.e., hampering the spread of the infection
by reducing the number of viable virus particles pro-
FIG. 6. Low levels of infectious HIV-1 particles in ribozyme-express- duced from infected cells. The resistance was, however,
ing HUT78 clones. Serial dilutions of supernatants from Day 14 (12.5 clearly dose dependent and could be at least partly
TCID50) of experiment 2 (Figs. 4E –4H) were used for infection of HUT78 overridden by a high initial viral load.cells. Viral infection was scored by presence of p24 in the cultures 7
As described in the Introduction, similar results havedays after the infection and a TCID50 value per milliliter of supernatant
was calculated. The cutoff value was 10 TCID50 . previously been obtained by groups who targeted other
AID VY 7880 / 6a15$$$283 04-04-96 11:40:18 vira AP: Virology
168 LARSSON ET AL.
regions of the HIV RNA. Wong-Staal and colleagues used expressed over several generations (Larsson et al., 1994;
G. Hotchkiss et al., to be published), supporting the con-a hairpin ribozyme directed against the HIV-1 LTR region
(Yu et al., 1993). They also tested a selection of promoters cept of stem cell therapy with hammerhead ribozymes.
to express the hairpin ribozyme and found a positive
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